![]() |
|
|
Vol. 281, Issue 1, 597-603, 1997
Section of Neurobiology (M.S.L., P.S.G.) and
Department of
Pharmacology (J.D.L.), Yale University School of Medicine, New
Haven, Connecticut
D2 dopamine receptor antagonism is postulated to be the key to
antipsychotic efficacy in the treatment of schizophrenia. Yet the D1
dopamine family of receptors is far more prevalent in the cortical
areas of the brain, such as the prefrontal cortex, which have
frequently been implicated in schizophrenia. Moreover, the prefrontal
cortical D1 sites have recently been shown to be down-regulated by
chronic treatment with several commonly used antipsychotic drugs (). To provide further insight into the
pharmacological regulation of the D1 class of dopaminergic receptors,
we have now used ribonuclease protection assays to examine the
regulation of D1 and D5 dopamine receptor mRNAs in the prefrontal
cortex and the neostriatum of nonhuman primates after chronic treatment
with eight different drugs representing a wide structural and
pharmacological spectrum of antipsychotic medications. The medications
were administered for 6 months twice daily at doses that fall within
the therapeutic range recommended for human patients. The study also
included a substituted benzamide, tiapride, which is a D2 antagonist
like the eight aforementioned drugs but reportedly lacks antipsychotic
activity. Remarkably, all drugs used in this study, including tiapride,
down-regulated the levels of both D1 and D5 mRNAs in the prefrontal
cortex by 30% to 60% compared with a vehicle control group, whereas
mRNAs in the neostriatum were not affected. This observation indicates that a reduction in the levels of prefrontal cortical dopamine receptors of the D1 class may be an obligatory consequence of D2
receptor antagonism and thus may be a pharmacological property of
antipsychotic drugs.